Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 25;21(11):2552–2560. doi: 10.1038/s41436-019-0522-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 2 — Decrease in biochemical abnormality from pretreatment to last follow-up. Percent change in biochemical abnormalities in the cerebrospinal fluid from time point 1 to 4, i.e., before any treatment to final intrathecal recombinant iduronidase infusion, 6 months posttransplant. All reductions were significant at p < 0.0001. Nonreducing ends (NREs) I0S0 and I0S6 (N = 20, N = 19, respectively) separately showed significant reductions, by more than 80% for I0S0 and 54% for I0S6. Heparan sulfate (HS, N = 20) decreased by 30%, and heparin cofactor II–thrombin complex (HCIIT, N = 19) decreased by more than half. CI confidence interval.